Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT06991257 | A Study to Learn About the Study Medicine Called PF-07328948 in Adults With Heart Failure (BRANCH-HF) | PHASE2 | RECRUITING | 620 | — | — | Jun 19, 2025 | Dec 14, 2027 | May 27, 2026 | 142 | United States, Brazil +11 |
Adjudicated cardiovascular death and worsening heart failure events through 36 weeks.
A submaximal exercise test that measures the distance the participant can walk within prescribed time of 6 minutes. Participants are asked to perform the test at a pace comfortable to them with as many breaks as needed. The total distance walked is recorded.
KCCQ is a 23-item heart-failure specific questionnaire quantified into the following scores: symptom frequency, symptom burden, symptom stability, physical limitations, social limitations, quality of life, and self-efficacy, total symptom score, overall summary score, and clinical summary score. To facilitate interpretation, all scores are presented on a scale of 0 to 100 points, with lower scores indicating more severe symptoms and/or limitations, and a score of 100 indicating no symptoms, no limitations, and excellent quality of life.
| Arm | Type | Description |
|---|---|---|
| ARM 1 | PLACEBO_COMPARATOR | Placebo Participants will receive Placebo for up to 36 weeks |
| ARM 2 | EXPERIMENTAL | Low dose PF-07328948 Participants will receive PF-07328948 for up to 36 weeks |
| ARM 3 | EXPERIMENTAL | Medium dose PF-07328948 Participants will receive PF-07328948 for up to 36 weeks |
| ARM 4 | EXPERIMENTAL | High dose PF-07328948 Participants will receive PF-07328948 for up to 36 weeks |
| Name | Type | Description |
|---|---|---|
| Placebo | DRUG | ARM 1 |
| Low Dose PF-07328948 | DRUG | ARM 2 |
| Medium Dose PF-07328948 | DRUG | ARM 3 |
| High Dose PF-07328948 | DRUG | ARM 4 |
This study is seeking participants who are: Key Inclusion Criteria include: * aged 18 years to \< 80 years * clinically confirmed to have a diagnosis of heart failure for at least 3 months * New York Heart Association Class II-IV symptoms * left ventricular ejection fraction greater than 40% * Kan...